Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)